Peptide Elongation Factor 1 (1, EF)

Peptide elongation factor 1 is a multisubunit protein that is responsible for the GTP-dependent binding of aminoacyl-tRNAs to eukaryotic ribosomes. The alpha subunit (EF-1alpha) binds aminoacyl-tRNA and transfers it to the ribosome in a process linked to GTP hydrolysis. The beta and delta subunits (EF-1beta, EF-1delta) are involved in exchanging GDP for GTP. The gamma subunit (EF-1gamma) is a structural component.

Also Known As:

Networked: 113 relevant articles (4 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ju, Zhenyu: 2 articles (08/2010 - 08/2008)
2.	Song, Zhangfa: 2 articles (08/2010 - 08/2008)
3.	Liu, Yan: 2 articles (08/2010 - 07/2005)
4.	Costa, Sarah S: 1 article (01/2016)
5.	Matos, Kedma S: 1 article (01/2016)
6.	Seixas, Claudine D S: 1 article (01/2016)
7.	Pfenning, Ludwig H: 1 article (01/2016)
8.	Tessmann, Dauri J: 1 article (01/2016)
9.	Lyu, Qixue: 1 article (09/2015)
10.	He, Siyu: 1 article (09/2015)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2006 - "Also, the anti-cancer efficacy of HSV-TK/GCV therapy with the hHKII-targeted vector was comparable to that obtained with the control vector that utilized a commonly used constitutive promoter from the human elongation factor 1 alpha (hEF1alpha) gene. " 11/01/2009 - "In the present study, we investigate the influence of EF-1alpha in Du145, a high-grade metastatic PCa cell line, and demonstrate that EF-1alpha plays an essential role in cellular properties associated with tumor progression, namely cell proliferation, invasion, and migration. " 08/24/2015 - "Nannocystin A: an Elongation Factor 1 Inhibitor from Myxobacteria with Differential Anti-Cancer Properties." 11/01/2009 - "Taken together, these findings support the hypothesis that EF-1alpha affects multiple processes involved in tumor progression, and identify EF-1alpha as a potential therapeutic target." 09/01/2008 - "Absence of somatic mutation of a tumor suppressor gene eukaryotic translation elongation factor 1, epsilon-1 (EEF1E1), in common human cancers."
2.	Kidney Diseases (Kidney Disease) 01/01/2014 - "The aim of the present study was to appraise the diagnostic efficacy of age, estimated glomerular filtration rate (eGFR) and ejection fraction (AGEF) score (age/EF(%)+1 (if eGFR was <60 ml × min(-1)× 1.73 m(-2))) as an predictor of CIAKI in patients with diabetes mellitus (DM) and concomitant chronic kidney disease (CKD). "
3.	Diabetes Mellitus 01/01/2014 - "The aim of the present study was to appraise the diagnostic efficacy of age, estimated glomerular filtration rate (eGFR) and ejection fraction (AGEF) score (age/EF(%)+1 (if eGFR was <60 ml × min(-1)× 1.73 m(-2))) as an predictor of CIAKI in patients with diabetes mellitus (DM) and concomitant chronic kidney disease (CKD). "
4.	Cysts 03/07/1983 - "In the course of a structural analysis of the alpha-chain of elongation factor 1 from Artemia salina cysts, we present four amino acid sequences comprising together half of the polypeptide chain. " 07/01/1976 - "The results obtained indicate that EF-1alpha is present as a predominant species in all the tissues examined, such as pig liver, rat liver, rabbit reticulocytes, and Artemia salina cysts. " 09/01/1999 - "The higher percentage of humoral immune response against Eg EF-1beta/delta observed in CE patients with calcified cysts than in patients with active cysts indicates the possible release of the protein in the hydatid fluid after protoscoleces degeneration suggesting the possible use of this antigen in the immunosurveillance of CE. " 06/18/1985 - "Relative levels of mRNA coding for eL12, eL12' and elongation factor 1 alpha were determined during the development of Artemia from a dormant cyst to a nauplius. " 10/16/1978 - "The low-molecular-weight form of elongation factor 1 (EF-1L) of the cysts of the brine shrimp Artemia salina and [3H]phenylalanyl-tRNA are able to form a stable complex which can be isolated on a Sephacryl S200 column. "
5.	Heart Failure 01/01/2001 - "Only the carvedilol group demonstrated a significant improvement in both heart failure functional class and LV ejection fraction (EF) 1 year after the start of medication. "

Related Drugs and Biologics

1.	Peptide Elongation Factor 1 (1, EF)
2.	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)
3.	carvedilol (Coreg)
4.	Proteins (Proteins, Gene)
5.	Messenger RNA (mRNA)
6.	Oxidoreductases
7.	Actins (F Actin)
8.	Complementary DNA (cDNA)
9.	Tubulin
10.	RNA Polymerase II (RNA Polymerase B)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Intravenous Injections